DK0772452T3 - Farmaceutisk formulering til subkutan, intramuskulær eller intradermal administration af faktor VIII - Google Patents
Farmaceutisk formulering til subkutan, intramuskulær eller intradermal administration af faktor VIIIInfo
- Publication number
- DK0772452T3 DK0772452T3 DK95914669T DK95914669T DK0772452T3 DK 0772452 T3 DK0772452 T3 DK 0772452T3 DK 95914669 T DK95914669 T DK 95914669T DK 95914669 T DK95914669 T DK 95914669T DK 0772452 T3 DK0772452 T3 DK 0772452T3
- Authority
- DK
- Denmark
- Prior art keywords
- factor viii
- factor
- subcutaneous
- pct
- intramuscular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9401105A SE9401105D0 (sv) | 1993-07-05 | 1994-03-31 | Formulation |
SE9500036A SE9500036D0 (sv) | 1995-01-05 | 1995-01-05 | Formulation |
PCT/SE1995/000348 WO1995026750A1 (en) | 1994-03-31 | 1995-03-31 | Pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration of factor viii or factor ix |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0772452T3 true DK0772452T3 (da) | 2003-01-06 |
Family
ID=26662019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95914669T DK0772452T3 (da) | 1994-03-31 | 1995-03-31 | Farmaceutisk formulering til subkutan, intramuskulær eller intradermal administration af faktor VIII |
Country Status (19)
Country | Link |
---|---|
US (1) | US5925739A (da) |
EP (1) | EP0772452B1 (da) |
JP (1) | JP3939750B2 (da) |
AT (1) | ATE222770T1 (da) |
AU (1) | AU690666B2 (da) |
BR (1) | BRPI9507227B8 (da) |
CA (1) | CA2186126C (da) |
DE (1) | DE69527966T2 (da) |
DK (1) | DK0772452T3 (da) |
ES (1) | ES2182899T3 (da) |
FI (1) | FI118171B (da) |
HU (1) | HU223314B1 (da) |
IL (2) | IL113010A0 (da) |
NO (1) | NO321139B1 (da) |
NZ (1) | NZ283499A (da) |
PL (1) | PL180282B1 (da) |
PT (1) | PT772452E (da) |
TW (1) | TW400234B (da) |
WO (1) | WO1995026750A1 (da) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4430205A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung |
SE9403915D0 (sv) * | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
SE9502285D0 (sv) * | 1995-06-22 | 1995-06-22 | Pharmacia Ab | Improvements related to injections |
US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
EP0954326B2 (en) * | 1996-04-19 | 2009-07-22 | Grifols Inc. | A process for viral inactivation of lyophilized blood proteins |
US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
US20050032690A1 (en) * | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
US7786070B2 (en) | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
WO2001082943A2 (en) | 2000-05-03 | 2001-11-08 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor vii |
DK2193809T3 (da) | 1999-02-22 | 2015-05-26 | Univ Connecticut | Albumin-frie faktor-VIII-formuleringer |
US20020156453A1 (en) * | 1999-10-14 | 2002-10-24 | Pettis Ronald J. | Method and device for reducing therapeutic dosage |
US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
JP4663837B2 (ja) * | 1999-12-24 | 2011-04-06 | 一般財団法人化学及血清療法研究所 | 第▲viii▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物 |
US20020123093A1 (en) | 2000-04-06 | 2002-09-05 | Zannis Vassilis I. | Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
HUP0402315A3 (en) * | 2001-12-21 | 2009-03-30 | Novo Nordisk Healthcare Ag | Liquid composition of factor vii polypeptides |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
CN1671410B (zh) | 2002-06-21 | 2010-05-12 | 诺和诺德医疗保健公司 | 因子ⅶ多肽的稳定化固体组合物 |
WO2004082708A2 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
CA2465004A1 (en) * | 2003-05-19 | 2004-11-19 | National Institute For Biological Standards And Control | Composition |
AU2004241698A1 (en) * | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
ES2382157T3 (es) * | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
ES2335994T3 (es) * | 2003-07-01 | 2010-04-07 | Novo Nordisk Health Care Ag | Composicion farmaceutica liquida, acuosa de polipeptidos factor vii. |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
CA2534028A1 (en) * | 2003-08-14 | 2005-02-24 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
EP3378470A1 (en) * | 2003-12-19 | 2018-09-26 | Novo Nordisk Health Care AG | Stabilised compositions of factor vii polypeptides |
FR2868704B1 (fr) * | 2004-04-07 | 2007-09-14 | Ethypharm Sa | Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires |
SI1750733T1 (sl) | 2004-05-03 | 2014-03-31 | Emory University | POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
PL1824988T3 (pl) * | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
WO2006103298A2 (en) * | 2005-04-01 | 2006-10-05 | Novo Nordisk Health Care Ag | Blood coagulation fviii analogues |
US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
US20080242607A1 (en) | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
JP5558106B2 (ja) * | 2007-01-03 | 2014-07-23 | ノボ ノルディスク ヘルス ケア アーゲー | 凝固第vii因子関連ポリペプチドの皮下投与 |
KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 g―csf를 이용하는 치료 방법 |
US8187799B2 (en) * | 2007-04-26 | 2012-05-29 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
EP2486936A1 (en) | 2007-06-13 | 2012-08-15 | CSL Behring GmbH | A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders |
US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
CA2740793A1 (en) * | 2008-11-03 | 2010-06-03 | Haiyan Jiang | Method for the treatment of hemophilia |
MX339060B (es) | 2008-11-07 | 2016-05-09 | Baxter Int | Formulaciones del factor viii. |
US20120148557A1 (en) * | 2009-08-20 | 2012-06-14 | Ulrich Kronthaler | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
ES2721478T3 (es) | 2010-11-05 | 2019-07-31 | Baxalta Inc | Nueva variante del factor VIII antihemofílico que tiene actividad específica aumentada |
AU2012318279B2 (en) | 2011-10-18 | 2015-06-04 | Csl Behring Gmbh | Use of sulfated glycosaminoglycans for improving the bioavailability of Factor VIII |
JP6029674B2 (ja) | 2011-10-18 | 2016-11-24 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第viii因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用 |
SG11201406492YA (en) * | 2012-04-16 | 2014-11-27 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
WO2013083858A1 (en) | 2012-04-24 | 2013-06-13 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
AU2013203062C1 (en) | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
TWI629993B (zh) * | 2013-03-15 | 2018-07-21 | 美商生物化學醫療公司 | 因子viii多肽調配物 |
DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
EP3152230B1 (en) | 2014-06-06 | 2019-08-07 | Octapharma AG | Preparation comprising factor viii and von willebrand factor peptides |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
EP3481416B1 (en) | 2016-07-08 | 2020-09-09 | CSL Behring Lengnau AG | Subcutaneous administration of long-acting factor ix in humans |
TW201828974A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Csl貝林重組技能公司 | 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類 |
CN114929261A (zh) | 2020-02-17 | 2022-08-19 | 生物测试股份公司 | 凝血因子viii的皮下施用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56127308A (en) * | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical |
US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
FI86885C (fi) * | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
SE8501050D0 (sv) * | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
US5576194A (en) * | 1986-07-11 | 1996-11-19 | Bayer Corporation | Recombinant protein production |
SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
NL9001681A (nl) * | 1990-07-24 | 1992-02-17 | Rijksuniversiteit | Transmucosale geneesmiddelpreparaten en transmucosale toediening. |
DE69227607T2 (de) * | 1991-07-10 | 1999-04-15 | Takeda Chemical Industries Ltd | Arzneimittel auf Basis von Hyaluronsäure |
GB9122609D0 (en) * | 1991-10-24 | 1991-12-04 | Brownlee George G | Improvements relating to the treatment of haemophilia |
EP0638091B1 (en) * | 1992-04-30 | 2005-12-07 | Probitas Pharma Inc. | Improved solubilization and stabilization of factor viii complex |
GB9211538D0 (en) * | 1992-06-01 | 1992-07-15 | Blake David R | Antiinflammatory agent |
DK0627924T3 (da) * | 1992-10-02 | 2001-04-30 | Genetics Inst | Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator |
SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
-
1995
- 1995-03-16 IL IL11301095A patent/IL113010A0/xx unknown
- 1995-03-16 IL IL11301099A patent/IL113010A/xx not_active IP Right Cessation
- 1995-03-17 TW TW084102570A patent/TW400234B/zh not_active IP Right Cessation
- 1995-03-31 CA CA002186126A patent/CA2186126C/en not_active Expired - Fee Related
- 1995-03-31 DE DE69527966T patent/DE69527966T2/de not_active Expired - Lifetime
- 1995-03-31 WO PCT/SE1995/000348 patent/WO1995026750A1/en active IP Right Grant
- 1995-03-31 AT AT95914669T patent/ATE222770T1/de active
- 1995-03-31 ES ES95914669T patent/ES2182899T3/es not_active Expired - Lifetime
- 1995-03-31 PL PL95316618A patent/PL180282B1/pl not_active IP Right Cessation
- 1995-03-31 JP JP52561695A patent/JP3939750B2/ja not_active Expired - Fee Related
- 1995-03-31 PT PT95914669T patent/PT772452E/pt unknown
- 1995-03-31 DK DK95914669T patent/DK0772452T3/da active
- 1995-03-31 HU HU9602693A patent/HU223314B1/hu not_active IP Right Cessation
- 1995-03-31 US US08/716,140 patent/US5925739A/en not_active Expired - Lifetime
- 1995-03-31 EP EP95914669A patent/EP0772452B1/en not_active Expired - Lifetime
- 1995-03-31 NZ NZ283499A patent/NZ283499A/xx not_active IP Right Cessation
- 1995-03-31 BR BRPI9507227A patent/BRPI9507227B8/pt not_active IP Right Cessation
- 1995-03-31 AU AU21560/95A patent/AU690666B2/en not_active Ceased
-
1996
- 1996-09-27 FI FI963871A patent/FI118171B/fi not_active IP Right Cessation
- 1996-09-27 NO NO19964081A patent/NO321139B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL316618A1 (en) | 1997-01-20 |
JP3939750B2 (ja) | 2007-07-04 |
MX9604455A (es) | 1997-07-31 |
EP0772452B1 (en) | 2002-08-28 |
CA2186126A1 (en) | 1995-10-12 |
FI963871A (fi) | 1996-09-27 |
PT772452E (pt) | 2003-01-31 |
FI118171B (fi) | 2007-08-15 |
TW400234B (en) | 2000-08-01 |
HU223314B1 (hu) | 2004-05-28 |
HU9602693D0 (en) | 1996-11-28 |
NO321139B1 (no) | 2006-03-27 |
DE69527966D1 (de) | 2002-10-02 |
NO964081D0 (no) | 1996-09-27 |
WO1995026750A1 (en) | 1995-10-12 |
ES2182899T3 (es) | 2003-03-16 |
AU690666B2 (en) | 1998-04-30 |
EP0772452A1 (en) | 1997-05-14 |
AU2156095A (en) | 1995-10-23 |
FI963871A0 (fi) | 1996-09-27 |
NZ283499A (en) | 1997-08-22 |
BR9507227A (pt) | 1997-09-09 |
CA2186126C (en) | 2007-11-20 |
ATE222770T1 (de) | 2002-09-15 |
HUT74918A (en) | 1997-03-28 |
BRPI9507227B8 (pt) | 2015-12-08 |
IL113010A (en) | 1999-10-28 |
PL180282B1 (pl) | 2001-01-31 |
DE69527966T2 (de) | 2003-05-28 |
JPH10501522A (ja) | 1998-02-10 |
NO964081L (no) | 1996-11-29 |
IL113010A0 (en) | 1995-10-31 |
US5925739A (en) | 1999-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0772452T3 (da) | Farmaceutisk formulering til subkutan, intramuskulær eller intradermal administration af faktor VIII | |
DK0710114T3 (da) | Koagulationsfaktor VIII-formulering | |
DE69132688D1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
DK0913156T3 (da) | Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis | |
DE69001686D1 (de) | Behandlung von leukozytstoerungen mit gm-csf. | |
EP1719522B1 (en) | Medicinal composition comprising TCF-II | |
ATE279937T1 (de) | Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung | |
KR870010871A (ko) | 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 | |
KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 |